Overview

Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy

Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
A randomized double blind phase III trial of Pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or following prior therapy
Phase:
Phase 3
Details
Lead Sponsor:
GlaxoSmithKline